Vaccines against gonorrhea: Current status and future challenges

Vaccine

Volumn 32, Issue 14, 2014, Pages 1579-1587

  Jerse, Ann E ^a   Bash, Margaret C ^b   Russell, Michael W ^c  

^a Uniformed Services University of the Health Sciences   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antibodies; Gonococcal antigens; Immune regulation; Immunity; Innate defenses; T cells

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT FACTOR H; CRYOPYRIN; GLYCOSYLTRANSFERASE; GONORRHEA VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; NITRITE REDUCTASE; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANAEROBIC GROWTH; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTIGENIC VARIATION; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIUM ADHERENCE; BACTERIUM PILUS; CARBOXY TERMINAL SEQUENCE; CELL DEATH; DENITRIFICATION; EPITHELIUM CELL; EXUDATE; GONORRHEA; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNIZATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PYRONECROSIS; REGULATORY T LYMPHOCYTE; TH17 CELL; TWITCHING MOTILITY;

ANTIBODIES; GONOCOCCAL ANTIGENS; IMMUNE REGULATION; IMMUNITY; INNATE DEFENSES; T CELLS;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; FEMALE; GONORRHEA; HUMANS; IMMUNITY, INNATE; MICE; MICE, TRANSGENIC; NEISSERIA GONORRHOEAE; TH1 CELLS; VACCINATION;

EID: 84896725748     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.067     Document Type: Article

References (107)

1. Westrom L.V. Sexually transmitted diseases and infertility. Sex Transm Dis 1994, 21:S32-S37.
2. Campbell M.F. The surgical pathology of epididymitis. Ann Surg 1928, 88:98-111.
3. Woods C.R. Gonococcal infections in neonates and young children. Semin Pediatr Infect Dis 2005, 16:258-270.
4. Jarvis GA, Chang T.L. Modulation of HIV transmission by Neisseria gonorrhoeae: molecular and immunological aspects. Curr HIV Res 2012, 10:211-217.
5. World Health Organization Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae 2012, World Health Organization, Geneva.
6. Unemo M., Nicholas R.A. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012, 7:1401-1422.
7. Cohen M.S., Hoffman I.F., Royce R.A., Kazembe P., Dyer J.R., Daly C.C., et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997, 349:1868-1873.
8. Ebrahim S.H., McKenna M.T., Marks J.S. Sexual behaviour: related adverse health burden in the United States. Sex Transm Infect 2005, 81:38-40.
9. Ndowa F., Lusti-Narasimhan M. The threat of untreatable gonorrhoea: implications and consequences for reproductive and sexual morbidity. Reprod Health Matters 2012, 20:76-82.
10. Tapsall J.W. Antimicrobial resistance in Neisseria gonorrhoeae 2001, World Health Organization, Geneva.
11. Grosskurth H., Mosha F., Todd J., Mwijarubi E., Klokke A., Senkoro K., et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995, 346:530-536.
12. Madore D.V. Impact of immunization on Haemophilus influenzae type b disease. Infect Agents Dis 1996, 5:8-20.
13. Chan C.H., McCabe C.J., Fisman D.N. Core groups, antimicrobial resistance and rebound in gonorrhoea in North America. Sex Transm Infect 2012, 88:200-204.
14. Cahoon L.A., Seifert H.S. Focusing homologous recombination: pilin antigenic variation in the pathogenic Neisseria. Mol Microbiol 2011, 81:1136-1143.
15. Edwards J.L., Apicella M.A. The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women. Clin Microbiol Rev 2004, 17:965-981.
16. Sadarangani M., Pollard A.J., Gray-Owen S.D. Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria. FEMS Microbiol Rev 2011, 35:498-514.
17. Rechner C., Kuhlewein C., Muller A., Schild H., Rudel T. Host glycoprotein Gp96 and scavenger receptor SREC interact with PorB of disseminating Neisseria gonorrhoeae in an epithelial invasion pathway. Cell Host Microbe 2007, 2:393-403.
18. Schryvers A.B., Stojiljkovic I. Iron acquisition systems in the pathogenic Neisseria. Mol Microbiol 1999, 32:1117-1123.
19. Shafer W.M., Veal W.L., Lee E.H., Zarantonelli L., Balthazar J.T., Rouquette C. Genetic organization and regulation of antimicrobial efflux systems possessed by Neisseria gonorrhoeae and Neisseria meningitidis. J Mol Microbiol Biotechnol 2001, 3:219-224.
20. Gill M.J., McQuillen D.P., van Putten J.P., Wetzler L.M., Bramley J., Crooke H., et al. Functional characterization of a sialyltransferase-deficient mutant of Neisseria gonorrhoeae. Infect Immun 1996, 64:3374-3378.
21. Massari P., Ram S., Macleod H., Wetzler L.M. The role of porins in neisserial pathogenesis and immunity. Trends Microbiol 2003, 11:87-93.
22. Shafer W.M., Datta A., Kolli V.S., Rahman M.M., Balthazar J.T., Martin L.E., et al. Phase variable changes in genes lgtA and lgtC within the lgtABCDE operon of Neisseria gonorrhoeae can modulate gonococcal susceptibility to normal human serum. J Endotoxin Res 2002, 8:47-58.
23. Criss A.K., Seifert H.S. A bacterial siren song: intimate interactions between Neisseria and neutrophils. Nat Rev Microbiol 2012, 10:178-190.
24. Packiam M., Veit S.J., Anderson D.J., Ingalls R.R., Jerse A.E. Mouse strain-dependent differences in susceptibility to Neisseria gonorrhoeae infection and induction of innate immune responses. Infect Immun 2010, 78:433-440.
25. Ramsey K.H., Schneider H., Kuschner R.A., Trofa A.F., Cross A.S., Deal C.D. Inflammatory cytokine response to experimental human infection with Neisseria gonorrhoeae. Ann N Y Acad Sci 1994, 730:322-325.
26. Hedges S.R., Sibley D.A., Mayo M.S., Hook E.W., Russell M.W. Cytokine and antibody responses in women infected with Neisseria gonorrhoeae: effects of concomitant infections. J Infect Dis 1998, 178:742-751.
27. Feinen B., Jerse A.E., Gaffen S.L., Russell M.W. Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection. Mucosal Immunol 2010, 3:312-321.
28. Packiam M., Wu H., Veit S.J., Mavrogiorgos N., Jerse A.E., Ingalls R.R. Protective role of Toll-like receptor 4 in experimental gonococcal infection of female mice. Mucosal Immunol 2012, 5:19-29.
29. van Vliet S.J., Garcia-Vallejo J.J., van Kooyk Y. Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses. Immunol Cell Biol 2008, 86:580-587.
30. Fisette P.L., Ram S., Andersen J.M., Guo W., Ingalls R.R. The Lip lipoprotein from Neisseria gonorrhoeae stimulates cytokine release and NF-kappaB activation in epithelial cells in a Toll-like receptor 2-dependent manner. J Biol Chem 2003, 278:46252-46260.
31. Singleton T.E., Massari P., Wetzler L.M. Neisserial porin-induced dendritic cell activation is MyD88 and TLR2 dependent. J Immunol 2005, 174:3545-3550.
32. Zhu W., Ventevogel M.S., Knilans K.J., Anderson J.E., Oldach L.M., McKinnon K.P., et al. Neisseria gonorrhoeae suppresses dendritic cell-induced, antigen-dependent CD4 T cell proliferation. PLoS ONE 2012, 7:e41260.
33. Duncan J.A., Gao X., Huang M.T., O'Connor B.P., Thomas C.E., Willingham S.B., et al. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. J Immunol 2009, 182:6460-6469.
34. Hedges S.R., Mayo M.S., Mestecky J., Hook E.W., Russell M.W. Limited local and systemic antibody responses to Neisseria gonorrhoeae during uncomplicated genital infections. Infect Immun 1999, 67:3937-3946.
35. Zhu W., Chen C.J., Thomas C.E., Anderson J.E., Jerse A.E., Sparling P.F. Vaccines for gonorrhea: can we rise to the challenge?. Front Microbiol 2011, 2:124.
36. Imarai M., Candia E., Rodriguez-Tirado C., Tognarelli J., Pardo M., Perez T., et al. Regulatory T cells are locally induced during intravaginal infection of mice with Neisseria gonorrhoeae. Infect Immun 2008, 76:5456-5465.
37. Liu Y., Islam E.A., Jarvis G.A., Gray-Owen S.D., Russell M.W. Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-beta-dependent mechanisms. Mucosal Immunol 2012, 5:320-331.
38. Gagliardi M.C., Starnino S., Teloni R., Mariotti S., Dal Conte I., Di Carlo A., et al. Circulating levels of interleukin-17A and interleukin-23 are increased in patients with gonococcal infection. FEMS Immunol Med Microbiol 2011, 61:129-132.
39. Boulton I.C., Gray-Owen S.D. Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes. Nat Immunol 2002, 3:229-236.
40. Pantelic M., Kim Y.J., Bolland S., Chen I., Shively J., Chen T. Neisseria gonorrhoeae kills carcinoembryonic antigen-related cellular adhesion molecule 1 (CD66a)-expressing human B cells and inhibits antibody production. Infect Immun 2005, 73:4171-4179.
41. Youssef A.R., van der Flier M., Estevao S., Hartwig N.G., van der Ley P., Virji M. Opa+ and Opa- isolates of Neisseria meningitidis and Neisseria gonorrhoeae induce sustained proliferative responses in human CD4+ T cells. Infect Immun 2009, 77:5170-5180.
42. So N.S., Ostrowski M.A., Gray-Owen S.D. Vigorous response of human innate functioning IgM memory B cells upon infection by Neisseria gonorrhoeae. J Immunol 2012, 188:4008-4022.
43. Cohen M.S., Sparling P.F. Mucosal infection with Neisseria gonorrhoeae. Bacterial adaptation and mucosal defenses. J Clin Invest 1992, 89:1699-1705.
44. Britigan B.E., Cohen M.S., Sparling P.F. Gonococcal infection: a model of molecular pathogenesis. N Engl J Med 1985, 312:1683-1694.
45. Plummer F.A., Simonsen J.N., Chubb H., Slaney L., Kimata J., Bosire M., et al. Epidemiologic evidence for the development of serovar-specific immunity after gonococcal infection. J Clin Invest 1989, 83:1472-1476.
46. Fox K.K., Thomas J.C., Weiner D.H., Davis R.H., Sparling P.F., Cohen M.S. Longitudinal evaluation of serovar-specific immunity to Neisseria gonorrhoeae. Am J Epidemiol 1999, 149:353-358.
47. Rice P.A., Vayo H.E., Tam M.R., Blake M.S. Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum. J Exp Med 1986, 164:1735-1748.
48. Arko R.J. Animal models for pathogenic Neisseria species. Clin Microbiol Rev 1989, 2(Suppl):S56-S59.
49. Cohen M.S., Cannon J.G. Human experimentation with Neisseria gonorrhoeae: progress and goals. J Infect Dis 1999, 179(Suppl 2):S375-S379.
50. Hobbs M.M., Sparling P.F., Cohen M.S., Shafer W.M., Deal C.D., Jerse A.E. Experimental gonococcal infection in male volunteers: cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkC. Front Microbiol 2011, 2:123.
51. Schmidt K.A., Schneider H., Lindstrom J.A., Boslego J.W., Warren R.A., Van de Verg L., et al. Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers. Sex Transm Dis 2001, 28:555-564.
52. Johnson A.P., Tuffrey M., Taylor-Robinson D. Resistance of mice to genital infection with Neisseria gonorrhoeae. J Med Microbiol 1989, 30:33-36.
53. Jerse A.E., Wu H., Packiam M., Vonck R.A., Begum A.A., Garvin L.E. Estradiol-treated female mice as surrogate hosts for Neisseria gonorrhoeae genital tract infections. Front Microbiol 2011, 2:107.
54. Plante M., Jerse A., Hamel J., Couture F., Rioux C.R., Brodeur B.R., et al. Intranasal immunization with gonococcal outer membrane preparations reduces the duration of vaginal colonization of mice by Neisseria gonorrhoeae. J Infect Dis 2000, 182:848-855.
55. Blake M., Holmes K.K., Swanson J. Studies on gonococcus infection. XVII. IgA1-cleaving protease in vaginal washings from women with gonorrhea. J Infect Dis 1979, 139:89-92.
56. Hedges S.R., Mayo M.S., Kallman L., Mestecky J., Hook E.W., Russell M.W. Evaluation of immunoglobulin A1 (IgA1) protease and IgA1 protease-inhibitory activity in human female genital infection with Neisseria gonorrhoeae. Infect Immun 1998, 66:5826-5832.
57. Russell M.W., Mestecky J. Humoral immune responses to microbial infections in the genital tract. Microbes Infect 2002, 4:667-677.
58. Ngampasutadol J., Tran C., Gulati S., Blom A.M., Jerse E.A., Ram S., et al. Species-specificity of Neisseria gonorrhoeae infection: do human complement regulators contribute?. Vaccine 2008, 26(Suppl 8):I62-I66.
59. Granoff D.M., Welsch J.A., Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 2009, 77:764-769.
60. Price G.A., Masri H.P., Hollander A.M., Russell M.W., Cornelissen C.N. Gonococcal transferrin binding protein chimeras induce bactericidal and growth inhibitory antibodies in mice. Vaccine 2007, 25:7247-7260.
61. Price G.A., Russell M.W., Cornelissen C.N. Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice. Infect Immun 2005, 73:3945-3953.
62. Ishikawa F., Yasukawa M., Lyons B., Yoshida S., Miyamoto T., Yoshimoto G., et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chain(null) mice. Blood 2005, 106:1565-1573.
63. Boslego J.W., Tramont E.C., Chung R.C., McChesney D.G., Ciak J., Sadoff J.C., et al. Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine 1991, 9:154-162.
64. Cornelissen C.N., Kelley M., Hobbs M.M., Anderson J.E., Cannon J.G., Cohen M.S., et al. The transferrin receptor expressed by gonococcal strain FA1090 is required for the experimental infection of human male volunteers. Mol Microbiol 1998, 27:611-616.
65. Gulati S., McQuillen D.P., Mandrell R.E., Jani D.B., Rice P.A. Immunogenicity of Neisseria gonorrhoeae lipooligosaccharide epitope 2C7, widely expressed in vivo with no immunochemical similarity to human glycosphingolipids. J Infect Dis 1996, 174:1223-1237.
66. Ngampasutadol J., Rice P.A., Walsh M.T., Gulati S. Characterization of a peptide vaccine candidate mimicking an oligosaccharide epitope of Neisseria gonorrhoeae and resultant immune responses and function. Vaccine 2006, 24:157-170.
67. Banerjee A., Wang R., Uljon S.N., Rice P.A., Gotschlich E.C., Stein D.C. Identification of the gene (lgtG) encoding the lipooligosaccharide beta chain synthesizing glucosyl transferase from Neisseria gonorrhoeae. Proc Natl Acad Sci U S A 1998, 95:10872-10877.
68. Boulanger M.J., Murphy M.E. Crystal structure of the soluble domain of the major anaerobically induced outer membrane protein (AniA) from pathogenic Neisseria: a new class of copper-containing nitrite reductases. J Mol Biol 2002, 315:1111-1127.
69. Shewell L.K., Ku S.C., Schulz B.L., Jen F.E., Ketterer M.R., Apicella M.A., et al. Recombinant truncated AniA of pathogenic Neisseria elicits a non-native immune response and functional blocking antibodies. Biochem Biophys Res Commun 2013.
70. Clark V.L., Knapp J.S., Thompson S., Klimpel K.W. Presence of antibodies to the major anaerobically induced gonococcal outer membrane protein in sera from patients with gonococcal infections. Microb Pathog 1988, 5:381-390.
71. Falsetta M.L., Steichen C.T., McEwan A.G., Cho C., Ketterer M., Shao J., et al. The composition and metabolic phenotype of Neisseria gonorrhoeae biofilms. Front Microbiol 2011, 2:75.
72. Keiser P.B., Biggs-Cicatelli S., Moran E.E., Schmiel D.H., Pinto V.B., Burden R.E., et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011, 29:1413-1420.
73. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23:2191-2196.
74. Serruto D., Bottomley M.J., Ram S., Giuliani M.M., Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012, 30(Suppl 2):B87-B97.
75. Hadad R., Jacobsson S., Pizza M., Rappuoli R., Fredlund H., Olcen P., et al. Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae. APMIS 2012, 120:750-760.
76. Gallichan W.S., Rosenthal K.L. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995, 13:1589-1595.
77. Russell M.W., Moldoveanu Z., White P.L., Sibert G.J., Mestecky J., Michalek S.M. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit. Infect Immun 1996, 64:1272-1283.
78. Wu H.Y., Abdu S., Stinson D., Russell M.W. Generation of female genital tract antibody responses by local or central (common) mucosal immunization. Infect Immun 2000, 68:5539-5545.
79. Johansson E.L., Wassen L., Holmgren J., Jertborn M., Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 2001, 69:7481-7486.
80. Hapfelmeier S., Lawson M.A., Slack E., Kirundi J.K., Stoel M., Heikenwalder M., et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science 2010, 328:1705-1709.
81. Freytag L.C., Clements J.D. Mucosal adjuvants. Vaccine 2005, 23:1804-1813.
82. Hajishengallis G., Connell T.D. Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties. Vet Immunol Immunopathol 2012.
83. Hajishengallis G., Connell T.D. Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties. Vet Immunol Immunopathol 2013, 152:68-77.
84. Wu H.Y., Russell M.W. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun 1993, 61:314-322.
85. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000, 165:4778-4782.
86. Metzger D.W. IL-12 as an adjuvant for the enhancement of protective humoral immunity. Expert Rev Vaccines 2009, 8:515-518.
87. Thompson A.L., Staats H.F. Cytokines: the future of intranasal vaccine adjuvants. Clin Dev Immunol 2011, 2011:289597.
88. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011, 10:499-511.
89. Rahman M., Kallstrom H., Normark S., Jonsson A.B. PilC of pathogenic Neisseria is associated with the bacterial cell surface. Mol Microbiol 1997, 25:11-25.
90. Rudel T., Scheurerpflug I., Meyer T.F. Neisseria PilC protein identified as type-4 pilus tip-located adhesin. Nature 1995, 373:357-359.
91. Haghi F., Peerayeh S.N., Siadat S.D., Zeighami H. Recombinant outer membrane secretin PilQ(406-770) as a vaccine candidate for serogroup B Neisseria meningitidis. Vaccine 2012, 30:1710-1714.
92. Callaghan M.J., Lewis S., Sadarangani M., Bailey S.E., Chan H., Ferguson D.J., et al. Potential of recombinant Opa proteins as vaccine candidates against hyperinvasive meningococci. Infect Immun 2011, 79:2810-2818.
93. de Jonge M.I., Hamstra H.J., Jiskoot W., Roholl P., Williams N.A., Dankert J., et al. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. Vaccine 2004, 22:4021-4028.
94. Cole J.G., Jerse A.E. Functional characterization of antibodies against Neisseria gonorrhoeae opacity protein loops. PLoS ONE 2009, 4:e8108.
95. Cornelissen C.N., Hollander A. TonB-dependent transporters expressed by Neisseria gonorrhoeae. Front Microbiol 2011, 2:117.
96. Stork M., Bos M.P., Jongerius I., de Kok N., Schilders I., Weynants V.E., et al. An outer membrane receptor of Neisseria meningitidis involved in zinc acquisition with vaccine potential. PLoS Pathog 2010, 6:e1000969.
97. Shell D.M., Chiles L., Judd R.C., Seal S., Rest R.F. The Neisseria lipooligosaccharide-specific alpha-2,3-sialyltransferase is a surface-exposed outer membrane protein. Infect Immun 2002, 70:3744-3751.
98. Serino L., Nesta B., Leuzzi R., Fontana M.R., Monaci E., Mocca B.T., et al. Identification of a new OmpA-like protein in Neisseria gonorrhoeae involved in the binding to human epithelial cells and in vivo colonization. Mol Microbiol 2007, 64:1391-1403.
99. Zhu P., Klutch M.J., Derrick J.P., Prince S.M., Tsang R.S., Tsai C.M. Identification of opcA gene in Neisseria polysaccharea: interspecies diversity of Opc protein family. Gene 2003, 307:31-40.
100. Liu Y., Russell M.W. Diversion of the immune response to Neisseria gonorrhoeae from Th17 to Th1/Th2 by treatment with anti-transforming growth factor beta antibody generates immunological memory and protective immunity. MBio 2011, 2. e00095-11.
101. Liu Y., Feinen B., Russell M.W. New concepts in immunity to Neisseria gonorrhoeae: innate responses and suppression of adaptive immunity favor the pathogen, not the host. Front Microbiol 2011, 2:52.
102. Koch M.L. A study of cervical cultures taken in cases of acute gonorrhea with special reference to the phases of the menstrual cycle. Am J Obstet Gynecol 1947, 54:861-866.
103. McCormack W.M., Reynolds G.H. Effect of menstrual cycle and method of contraception on recovery of Neisseria gonorrhoeae. JAMA 1982, 247:1292-1294.
104. Cole J.G., Fulcher N.B., Jerse A.E. Opacity proteins increase Neisseria gonorrhoeae fitness in the female genital tract due to a factor under ovarian control. Infect Immun 2010, 78:1629-1641.
105. Edwards J.L. Neisseria gonorrhoeae survival during primary human cervical epithelial cell infection requires nitric oxide and is augmented by progesterone. Infect Immun 2010, 78:1202-1213.
106. Wiesenfeld H.C., Hillier S.L., Krohn M.A., Landers D.V., Sweet R.L. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis 2003, 36:663-668.
107. Muench D.F., Kuch D.J., Wu H., Begum A.A., Veit S.J., Pelletier M.E., et al. Hydrogen peroxide-producing lactobacilli inhibit gonococci in vitro but not during experimental genital tract infection. J Infect Dis 2009, 199:1369-1378.